Axsome Therapeutics (NASDAQ:AXSM) Director Mark Coleman Sells 5,537 Shares of Stock

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Director Mark Coleman sold 5,537 shares of the stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $223.39, for a total transaction of $1,236,910.43. Following the transaction, the director owned 29,603 shares in the company, valued at $6,613,014.17. The trade was a 15.76% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Mark Coleman also recently made the following trade(s):

• On Monday, June 1st, Mark Coleman sold 6,000 shares of Axsome Therapeutics stock. The shares were sold at an average price of $230.30, for a total transaction of $1,381,800.00.
• On Friday, May 29th, Mark Coleman sold 6,000 shares of Axsome Therapeutics stock. The shares were sold at an average price of $233.46, for a total transaction of $1,400,760.00.

Axsome Therapeutics Stock Down 3.5%

Shares of NASDAQ AXSM opened at $222.16 on Wednesday. Axsome Therapeutics, Inc. has a one year low of $96.09 and a one year high of $238.56. The company has a debt-to-equity ratio of 2.27, a current ratio of 1.39 and a quick ratio of 1.32. The firm’s 50 day simple moving average is $196.96 and its two-hundred day simple moving average is $176.15. The stock has a market capitalization of $11.43 billion, a P/E ratio of -59.56 and a beta of 0.61.

Axsome Therapeutics (NASDAQ:AXSM) last issued its quarterly earnings results on Monday, May 4th. The company reported ($1.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.41). Axsome Therapeutics had a negative net margin of 26.59% and a negative return on equity of 267.16%. The business had revenue of $191.20 million for the quarter, compared to the consensus estimate of $191.10 million. The company’s quarterly revenue was up 57.4% compared to the same quarter last year. As a group, analysts expect that Axsome Therapeutics, Inc. will post -2.14 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently issued reports on AXSM. Cantor Fitzgerald restated an “overweight” rating and issued a $272.00 target price on shares of Axsome Therapeutics in a report on Monday, May 4th. UBS Group raised their target price on shares of Axsome Therapeutics from $251.00 to $259.00 and gave the stock a “buy” rating in a report on Friday, April 10th. Mizuho raised their target price on shares of Axsome Therapeutics from $228.00 to $310.00 and gave the stock an “outperform” rating in a report on Tuesday, May 5th. Deutsche Bank Aktiengesellschaft set a $280.00 target price on shares of Axsome Therapeutics in a report on Tuesday, May 5th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Axsome Therapeutics in a report on Monday, April 20th. One analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $251.26.

Institutional Trading of Axsome Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its holdings in Axsome Therapeutics by 6.0% in the third quarter. Vanguard Group Inc. now owns 4,180,646 shares of the company’s stock valued at $507,739,000 after acquiring an additional 235,626 shares in the last quarter. Franklin Street Advisors Inc. NC bought a new stake in Axsome Therapeutics in the fourth quarter valued at $1,826,000. Aberdeen Group plc boosted its holdings in Axsome Therapeutics by 15.5% in the third quarter. Aberdeen Group plc now owns 94,648 shares of the company’s stock valued at $11,495,000 after acquiring an additional 12,732 shares in the last quarter. TD Asset Management Inc boosted its holdings in Axsome Therapeutics by 107.7% in the third quarter. TD Asset Management Inc now owns 44,192 shares of the company’s stock valued at $5,367,000 after acquiring an additional 22,914 shares in the last quarter. Finally, Pictet Asset Management Holding SA boosted its holdings in Axsome Therapeutics by 20.4% in the fourth quarter. Pictet Asset Management Holding SA now owns 436,063 shares of the company’s stock valued at $79,643,000 after acquiring an additional 73,925 shares in the last quarter. Institutional investors own 81.49% of the company’s stock.

About Axsome Therapeutics

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.